Key points are not available for this paper at this time.
Postapproval studies of drugs and devices are essential to identify late adverse events, but patients' privacy must be protected when EMR data are shared. This article discusses ways to balance the need for high-quality postapproval information and respect for patients' privacy.
Sarpatwari et al. (2014) studied this question.